Melagatran pharmacodynamics

Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran a mini-review. Thromb Res 2003 109(suppl I ) S9-S I 5. 

I Eriksson UG, Johansson S, Attman PO, et al. Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran. Clin Pharmacoki net 2003 42 743-753. 

Fager G, Cullberg M, Eriksson-Lepkowska M, et al. Pharmacokinetics and pharmacodynamics of melagatran, the active form ofthe oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003 59 283-289. 

Johansson LC, Andersson M, Fager G, et al, No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers. Clin Pharmacokinet 2003 42 475-484,... 

Gustafsson D, et al. The direct du ombin inhibitor melagatran and its oral prodrug H 376/95 intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb. Res. 2001 101 171-181. 

---